Target discovery: Blocking BTK in B-cell disorders

Nature Reviews Drug Discovery

Volumn 9, Issue 9, 2010, Pages 681-

  Flemming, Alexandra ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE INHIBITOR;

AUTOIMMUNITY; B CELL LYMPHOMA; B LYMPHOCYTE ACTIVATION; DOG; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; IMMUNOPATHOGENESIS; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 77956335423     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3262     Document Type: Short Survey

References (1)

1. Honigberg, L. A. et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl Acad. Sci. USA 107, 1307513080 (2010)